3-iodobenzylguanidine has been researched along with lutetium lu 177 dotatate in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bushnell, D | 1 |
| Buteau, FA; Makis, W; McCann, K; McEwan, AJ | 1 |
| Downie, P; Eu, P; Hicks, RJ; Hofman, MS; Hogg, A; Kong, G; Murray, WK; Super, L; Wilson, S; Wood, P | 1 |
| Bryanton, M; Makis, W; McCann, K; McEwan, AJ | 1 |
| Makis, W; McCann, K; McEwan, AJ | 1 |
| Caplin, M; Cheung, VTF; Khoo, B; Nastos, K; Navalkissoor, S; Quigley, AM; Toumpanakis, C | 1 |
| Du, Y; Falzone, N; Gill, MR; Vallis, KA | 1 |
| Gains, JE; Gaze, MN; Moroz, V; Sebire, NJ; Wheatley, K | 1 |
| Ahmadzadehfar, H; Alexander, N; Baruchel, S; Shammas, A; Vali, R | 1 |
| Ballinger, JR | 1 |
| Rowe, SP; Sadaghiani, MS; Sheikhbahaei, S; Solnes, LB | 1 |
4 review(s) available for 3-iodobenzylguanidine and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Targeted radionuclide therapy in combined-modality regimens.
Topics: 3-Iodobenzylguanidine; Antibodies, Monoclonal; Antineoplastic Agents; Chemoradiotherapy; DNA Repair; Humans; Immunotoxins; Microspheres; Molecular Targeted Therapy; Neoplasms; Octreotide; Organometallic Compounds; Radioisotopes; Radiotherapy; Radium | 2017 |
Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
Topics: 3-Iodobenzylguanidine; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neuroblastoma; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography | 2018 |
Theranostic radiopharmaceuticals: established agents in current use.
Topics: 3-Iodobenzylguanidine; Antigens, CD20; Bone Neoplasms; Dipeptides; Diphosphonates; Drug Approval; Forecasting; Heterocyclic Compounds, 1-Ring; Hodgkin Disease; Humans; Iodine Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Prostate-Specific Antigen; Radiopharmaceuticals; Somatostatin; Theranostic Nanomedicine; Thyroid Diseases | 2018 |
Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pheochromocytoma; Precision Medicine; Radiopharmaceuticals | 2021 |
7 other study(ies) available for 3-iodobenzylguanidine and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Humans; Octreotide; Organometallic Compounds | 2009 |
Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
Topics: 3-Iodobenzylguanidine; Adult; Antineoplastic Agents; Ascites; Bone Neoplasms; Disease Progression; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peritoneal Neoplasms; Radiopharmaceuticals | 2015 |
Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Immunohistochemistry; Male; Multimodal Imaging; Neuroblastoma; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
Topics: 3-Iodobenzylguanidine; Aged; Female; Heart Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thymus Neoplasms | 2015 |
Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
Topics: 3-Iodobenzylguanidine; Humans; Neuroendocrine Tumors; Octreotide; Orbital Neoplasms; Organometallic Compounds; Radiopharmaceuticals | 2016 |
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Topics: 3-Iodobenzylguanidine; Acute Kidney Injury; Adrenal Gland Neoplasms; Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Pheochromocytoma; Radiopharmaceuticals; Retrospective Studies; Yttrium Radioisotopes | 2017 |
Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.
Topics: 3-Iodobenzylguanidine; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Infant; Male; Molecular Targeted Therapy; Neuroblastoma; Octreotide; Organometallic Compounds | 2018 |